Issue 84

Psychedelic-assisted therapy at home

Telehealth harnesses telecommunications to enhance the accessibility of healthcare, delivering medical assistance to patients digitally.

Services experienced a surge in popularity during the COVID-19 pandemic, as a safer and more efficient alternative to visiting medical centres.

In recognition of this, the US government enabled healthcare providers to prescribe controlled medication virtually – opening the door for ketamine assisted therapy at home.

HOW PSYCHEDELIC MEDICINES MAY BE ABLE TO TREAT DEPRESSION

The BBC explores the latest research into psychedelic medicines and their mechanism of action.

FORMER CHIEF OF ADF ADVOCATES FOR MDMA-ASSISTED THERAPY

Australia’s former highest ranking military officer calls for veterans to be allowed MDMA to treat PTSD.

BUSINESS AND INVESTMENT

PharmaTher shares data from ketamine and betaine trial.

Cybin acquires DMT study from Etheon Biomedical.

Business Insider launches clinical trial tracker.

Optimi Health enters psilocybin supply agreement with ATMA Journey Centres.

Havn signs psilocybin supply agreement with Green Stripe.

Nova Mentis approved to export psilocybin analogue.

SCIENCE AND RESEARCH

Ketamine’s action on potassium channels in neurons.

Ceruvia to supply LSD to researchers for free.

Ketamine’s rapid action as an antidepressant.

REGULATION AND LEGISLATION

Patients push for access to psilocybin under Right to Try.

Oregon accepting applications from psilocybin training programmes.

Michigan activists scrap 2022 legalisation bill.

Oregon Boards reject rules allowing ceremonial psilocybin use.